Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Synchrony Financial (SYF) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Synchrony FinancialTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Synchrony Financial — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Synchrony Financial trades at $78.37 (market cap $25.53B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Synchrony Financial pays a 1.73% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYSYF
Market Cap
$29.60B$25.53B
Sector
HealthFinancials
52-Week High
$491.22$88.47
52-Week Low
$205.48$63.78
Enterprise Value
$27.56B
Dividend Yield
1.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Synchrony Financial

Synchrony Financial (SYF) trades at $79.41, up 1.56% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with a P/E of 8.05, net income margin of 23.4%, and consistent earnings beats in recent quarters. Recent Q2 2026 results showed $2.59 EPS, beating estimates by 24.5%, while the CareCredit partnership with Stripe expands financing access for health providers.

SYF presents attractive value with robust capital returns including aggressive buybacks and dividends. Analyst consensus is strongly bullish with a $86.33 price target representing 8.7% upside. Key risks include consumer credit deterioration and rising expenses, but stable purchase volume growth and improved net interest margin outlook support continued earnings growth potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.

Read more on SYF